Belantamab with pomalidomide and dexamethasone for multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new combination of drugs for people with multiple myeloma that has come back after previous treatment. The goal is to see if adding belantamab mafodotin to standard drugs can help control the disease better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a confirmed diagnosis of multiple myeloma.
- You must have had at least one previous line of treatment that included lenalidomide, and your disease must have progressed during or after that treatment.
- You must have measurable disease, such as a certain level of M-protein in your blood or urine, or an abnormal free light chain ratio.
- You must have adequate organ function, including blood counts, liver, and kidney function.
- You must not have had prior treatment with pomalidomide or belantamab mafodotin, and you must not have active infections or certain heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way of giving a combination of three drugs—belantamab mafodotin, bortezomib, and dexamethasone—for people with multiple myeloma that has come back or stopped responding to earlier treatments. The goal is to see if a different dosing schedule is more effective and safer.
This trial tests a new drug called belantamab mafodotin (a targeted antibody therapy) combined with standard treatments for multiple myeloma that has come back or stopped responding. It looks at three different drug combinations to see which works best for people who have had 1 or 2 prior treatments.
This study tests the safety and effectiveness of the drug belantamab, alone or with other treatments, for people with multiple myeloma that has come back or stopped responding to previous treatments.
This trial tests a new drug combination (belantamab mafodotin plus lenalidomide and dexamethasone) against the usual treatment for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. It aims to see if the new combination works better.
This trial tests a new combination of drugs for people with multiple myeloma whose cancer did not respond to or returned after one prior treatment with lenalidomide. The goal is to see if this combination is safe and effective.
This early-phase study tests how safe and effective belantamab mafodotin is when combined with lenalidomide and dexamethasone, plus a medicine called nirogacestat, in people with newly diagnosed multiple myeloma who cannot have stem cell transplant. It may help shrink the cancer and improve outcomes, while doctors track side effects.
Hear when a new Relapsed/Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.